Buyer for mid-sized manufacturing sites for small molecules or injectables in Europe

Company to buy

• Size: Medium business
• Sales: 10 – 50 million EUR
• Location: Europe
• Reason for acquisition: The management wants to expand their business in Europe
• #CFIE PHB240

Overview of buyer for mid-sized manufacturing sites for small molecules or injectables in Europe

The company is a global pharmaceutical company driven by a passion for improving the lives of patients around the world. Currently, they operate in over 15 countries with commercial partnerships in more than 100. Further, they offer a comprehensive suite of end-to-end pharmaceutical services, encompassing R&D, manufacturing, market access, and global commercialization. Altogether, their success stems from a powerful combination of a smart collaboration network and an unwavering commitment to delivering the highest quality, differentiated products and services to their partners.

Profile (strategy) of buyer for mid-sized manufacturing sites for small molecules or injectables in Europe

Primarily, this pharma company operates in more than 15 countries and has commercial partnerships with over 100. Essentially, the company is committed to the highest standards. In particular, their dedication to quality is evident in their state-of-the-art manufacturing facilities and rigorous quality control systems. Moreover, their cutting-edge facilities guarantee the highest quality production, ensuring patients receive safe and effective medications.

Critically, the company believes in pushing boundaries and breaking new ground. Likewise, their commitment to innovation fuels their research and development, leading to a pipeline of groundbreaking new products and services.

Overall, this company offers a comprehensive range of services, covering every step of the pharmaceutical journey including:

• R&D
• Manufacturing
• Market access
• Global commercialization

Activities and products of suitable targets

At this time, the company seeks a target with the capabilities to manufacture small molecules or injectables (peptides). In particular, using good manufacturing practice (GMP) compliant methods. More specifically, this requires having the necessary equipment, facilities, and personnel to meet all regulatory requirements. Moreover, a robust quality control and quality assurance system is essential to ensure the safety and efficacy of the products manufactured. Notably, this system should include procedures for testing raw materials, in-process materials, and finished products.

Ideally, the acquisition of a company with experience in related areas would be a strategic opportunity for the company. As a result, the company could expand its range of services and become an even more important player in the European market.

Highlights

• Global pharmaceutical company
• Network of offices in over 15 countries and commercial partnerships in more than 100 countries
• End-to-end pharmaceutical services including R&D, manufacturing, market access, and global commercialization
• Smart collaboration network for efficient operations
• Focus on high-value, difficult-to-make products
• Strong commitment to patient care and innovation

More information on this buyer for mid-sized manufacturing sites for small molecules or injectables in Europe

Please get in touch if you are interested in learning more about this buyer for mid-sized manufacturing sites for small molecules or injectables in Europe. For more cmo companies for sale please visit the section cmo companies for sale. For other cmo buyers, please visit the section cmo companies wanted. If you are instead interested in pharma companies for sale, please visit the pharma companies for sale section. For pharma buyers, please visit the section pharma companies wanted.